Alopecia Areata in a Patient Receiving Cemiplimab for Metastatic Cutaneous Squamous Cell Carcinoma

    June 2026 in “ JEADV Clinical Practice
    Marco Rubatto, Eleonora Bongiovanni, Veronica Arese … Marcella Occelli
    Studysummary In this case report, a 77-year-old woman developed alopecia areata after discontinuing cemiplimab treatment for metastatic cutaneous squamous cell carcinoma, suggesting an immune-related adverse effect potentially linked to systemic immune activation.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on onlinelibrary.wiley.com →
    Discuss this study in the Community →

    Research cited in this study 5

    1. From Mechanisms to Therapies: Current Advances and Breakthroughs in Alopecia Areata Immunopathology Frontiers in Immunology · 2025
    2. Alopecia and Hair Repigmentation Associated with Anti-Programmed Death-Ligand 1 (PD-L1) Immunotherapy JAAD Case Reports · 2024
    3. Trichoscopy Patterns in Alopecia Areata: A Systematic Review and Meta-Analysis Skin Research and Technology · 2023
    4. Cemiplimab-Induced Alopecia Areata International Journal of Trichology · 2023
    5. Immune-Related Alopecia (Areata and Universalis) in Cancer Patients Receiving Immune Checkpoint Inhibitors British journal of dermatology/British journal of dermatology, Supplement · 2016